- Home
- ELBM vs ATYR Comparison
ELBM vs ATYR Comparison
Compare ELBM & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELBM | ATYR |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | Canada | United States |
| Employees | N/A | 59 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 69.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ELBM | ATYR |
|---|---|---|
| Price | $1.03 | $0.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.15 | ★ $8.75 |
| AVG Volume (30 Days) | 795.0K | ★ 1.8M |
| Earning Date | 11-13-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $0.64 |
| 52 Week High | $8.70 | $7.29 |
Technical Indicators
Market Signals| Indicator | ELBM | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 42.84 |
| Support Level | $0.88 | $0.69 |
| Resistance Level | $0.97 | $0.74 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 77.67 | 26.02 |
Price Performance
Historical ComparisonAbout ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.